U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H10N2OS
Molecular Weight 170.232
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPYLTHIOURACIL

SMILES

CCCC1=CC(=O)NC(=S)N1

InChI

InChIKey=KNAHARQHSZJURB-UHFFFAOYSA-N
InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)

HIDE SMILES / InChI
Propylthiouracil is thyroid peroxidase inhibitor used to treat hyperthyroidism, which includes hyperthyroidism due to Graves' disease and toxic multinodular goiter. Propylthiouracil is used to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.38 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROPYLTHIOURACIL

Approved Use

Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.

Launch Date

1947
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.1 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.62 mg/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1385 μg × min/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.19 mg × h/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77 min
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.22 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPYLTHIOURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Bitter taste of saccharin and acesulfame-K.
2002-01
Neonatal thyroid enlargement associated with propylthiouracil therapy of Graves' disease during pregnancy: a problem revisited.
2001-12
Adverse effects of prenatal methimazole exposure.
2001-11
Treatment of acrodermatitis continua of Hallopeau with oral propylthiouracil and methotrexate.
2001-11
Altered cross-bridge characteristics following haemodynamic overload in rabbit hearts expressing V3 myosin.
2001-10-15
Thyroidal regulation of different isoforms of NaKATPase in glial cells of developing rat brain.
2001-10-05
Relationship of papillae number to bitter intensity of quinine and PROP within and between individuals.
2001-10
Thyroid hormone-induced oxidative damage on lipids, glutathione and DNA in the mouse heart.
2001-10
Binary taste mixture interactions in prop non-tasters, medium-tasters and super-tasters.
2001-10
Differential regulation of SR calcium transporters by thyroid hormone in rat atria and ventricles.
2001-10
Development and validation of a high-performance liquid chromatographic method for the analysis of propylthiouracil in pharmaceuticals.
2001-09
Ca(2+)/nicotinamide adenine dinucleotide phosphate-dependent H(2)O(2) generation is inhibited by iodide in human thyroids.
2001-09
Is the infertility in hypothyroidism mainly due to ovarian or pituitary functional changes?
2001-09
Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment.
2001-09
Thyroid status and leptin in Basedow-Graves and multinodular goiter patients.
2001-08-24
Myasthenia gravis in conjunction with Graves' disease: a diagnostic challenge.
2001-08-11
Interplay of pregnancy, lactation, and hyperthyroidism leading to severe osteoporosis in a young woman.
2001-08-11
The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line.
2001-08-10
Hypothyroidism and nutritional status alter 3,5,3'-triiodothyronine (T3) receptors in isolated liver nuclei of Anabas testudineus (Bloch).
2001-08
46, XY pure gonadal dysgenesis: a case with Graves' disease and exceptionally tall stature.
2001-08
Liver necrosis induced by thyroid hormone administration in rats fed ethanol.
2001-08
Increased intensity perception of aversive taste following right anteromedial temporal lobe removal in humans.
2001-08
Modulation of rat liver mitochondrial antioxidant defence system by thyroid hormone.
2001-07-27
Preparation and properties of a selenium-containing catalytic antibody as type I deiodinase mimic.
2001-07-27
Covariation in individuals' sensitivities to bitter compounds: evidence supporting multiple receptor/transduction mechanisms.
2001-07
Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation.
2001-07
Development of brief methods to classify individuals by PROP taster status.
2001-07
Regulation of TRH and TRH-related peptides in rat brain by thyroid and steroid hormones.
2001-07
Effects of oxidative stress on the erythrocyte Na+,K+ ATPase activity in female hyperthyroid patients.
2001-06-22
[Acute alcoholic hepatitis: treatments].
2001-06-09
Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis.
2001-06
Genetic taste responses to 6-n-propylthiouracil among adults: a screening tool for epidemiological studies.
2001-06
A selenium-containing catalytic antibody with Type I deiodinase activity.
2001-05-25
Myeloperoxidase-antineutrophil cytoplasmic antibody-associated sensorineural hearing loss.
2001-05
Short-term effects of thyroid hormones on lipogenic enzymes and 14C-acetate incorporation into various lipid classes: in vivo and in vitro studies.
2001-05
Fetal thyrotoxicosis after maternal thyroidectomy.
2001-05
Involvement of L-triiodothyronine in acetylcholine metabolism in adult rat cerebrocortical synaptosomes.
2001-05
[Pulmonary hypertension associated with refractory hyperthyroidism: a case report].
2001-05
Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
2001-05
Method for the analysis of thyreostats in meat tissue using gas chromatography with nitrogen phosphorus detection and tandem mass spectrometric confirmation.
2001-05
[Pregnancy (conception) in hyper- or hypothyroidism].
2001-04-14
Thiouracil antithyroid drugs as a new class of neuronal nitric oxide synthase inhibitors.
2001-04-06
Malignant hyperthermia in a patient with Graves' disease during subtotal thyroidectomy.
2001-04
Induction of autoimmune hypothyroidism and subsequent hyperthyroidism by TSH receptor antibodies following subacute thyroiditis: a case report.
2001-04
Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease.
2001-04
Arrhythmogenesis in isolated rat hearts with enhanced alpha-adrenoceptor-mediated responsiveness.
2001-02
Drug-induced congenital defects: strategies to reduce the incidence.
2001
Membrane-Bound and cytosolic forms of heterotrimeric G proteins in young and adult rat myocardium: influence of neonatal hypo- and hyperthyroidism.
2001
11Beta-hydroxysteroid dehydrogenase bioactivity is increased in the colon but not kidneys of rats given supplementary thyroxine.
2001
Liver disease caused by propylthiouracil.
1975-02
Patents

Sample Use Guides

Propylthiouracil is administered orally. The total daily dosage is usually given in 3 equal doses at approximately 8 hour intervals. The initial dose in adults is 300 mg daily. In patients with severe hyperthyroidism, very large goiters, or both, the initial dose may be increased to 400 mg daily; an occasional patient will require 600 to 900 mg daily initially. The usual maintenance dose is 100 to 150 mg daily.
Route of Administration: Oral
Thyroid peroxidase activity was measured by monitoring the formation of resorufin from the oxidation of Amplex Red.Assay mixtures (100 uL) contained 50 mM sodium phosphate buffer, pH 7.4, 150 mM NaCl, 2 uM H2O2, 30 uM Amplex Red, 1 mM diethylenetriaminepentaacetic acid, and 2% DMSO. The reactions were initiated by the addition of TPO. Reaction mixtures to determine the background reaction rate consisted of all assay components and 4 uL of 500 unit/mL bovine catalase in 50 mM potassium phosphate buffer, pH 7.0. The background rate was subtracted from each reaction progress curve. IC50 for propylthiouracil was 3.38 uM.
Name Type Language
NSC-6498
Preferred Name English
PROPYLTHIOURACIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
PROPYLTHIOURACIL [WHO-IP]
Common Name English
PROPYLTHIOURACIL [HSDB]
Common Name English
PROPYLTHIOURACIL [EP MONOGRAPH]
Common Name English
PROPYLTHIOURACIL [EP IMPURITY]
Common Name English
THYREOSTAT II
Common Name English
PROPYLTHIOURACIL [ORANGE BOOK]
Common Name English
PROPYLTHIOURACIL [JAN]
Common Name English
propylthiouracil [INN]
Common Name English
PROPYLTHIOURACIL [MART.]
Common Name English
6-Propyl-2-thiouracil
Systematic Name English
PROPYLTHIOURACIL [VANDF]
Common Name English
PROPYLTHIOURACIL [USP MONOGRAPH]
Common Name English
NSC-70461
Code English
Propylthiouracil [WHO-DD]
Common Name English
PROPYLTHIOURACIL [USP-RS]
Common Name English
PROPYLTHIOURACIL [MI]
Common Name English
PROPYLTHIOURACIL [IARC]
Common Name English
Classification Tree Code System Code
IARC Propylthiouracil
WHO-ATC H03BA02
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
NDF-RT N0000175917
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
EPA PESTICIDE CODE 57810
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
NDF-RT N0000175918
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 18.8
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
WHO-VATC QH03BA02
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
LIVERTOX NBK547973
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
NCI_THESAURUS C885
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
Code System Code Type Description
RXCUI
8794
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY RxNorm
CAS
51-52-5
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
DRUG BANK
DB00550
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
NCI_THESAURUS
C781
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
RS_ITEM_NUM
1578000
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
INN
4184
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
DAILYMED
721M9407IY
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
CHEBI
8502
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
LACTMED
Propylthiouracil
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL1518
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
EVMPD
SUB10123MIG
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-103-2
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
HSDB
3390
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
MESH
D011441
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
MERCK INDEX
m9250
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY Merck Index
SMS_ID
100000081364
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
IUPHAR
6650
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PROPYLTHIOURACIL
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY Description: Colourless or pale cream-coloured crystals or a white or cream-coloured, crystalline powder; odourless. Solubility: Very slightly soluble in water; sparingly soluble in ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Antithyroid substance. Storage: Propylthiouracil should be kept in a well-closed container, protected from light. Additional information: Propylthiouracil has a bitter taste. Definition: Propylthiouracil contains not less than 98.0% and not more than 100.5% of C7H10N2OS, calculated with reference tothe dried substance.
NSC
6498
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID5021209
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
FDA UNII
721M9407IY
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
PUBCHEM
657298
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
NSC
70461
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
DRUG CENTRAL
2308
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY
WIKIPEDIA
PROPYLTHIOURACIL
Created by admin on Mon Mar 31 17:49:58 GMT 2025 , Edited by admin on Mon Mar 31 17:49:58 GMT 2025
PRIMARY